MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/05/25
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/25
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025GlobeNewsWire • 10/29/25
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with DiabetesGlobeNewsWire • 10/13/25
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic CareGlobeNewsWire • 10/07/25
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical OfficerGlobeNewsWire • 09/29/25
SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHBusiness Wire • 09/16/25
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/08/25
MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/08/25
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled TherapyGlobeNewsWire • 08/27/25
MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/06/25
MannKind and Blackstone Announce up to $500 Million Strategic Financing AgreementGlobeNewsWire • 08/06/25
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business UpdateGlobeNewsWire • 08/06/25
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025GlobeNewsWire • 07/30/25
Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/30/25